KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Celltrion

Celltrion pushes for broader use of its COVID-19 treatment 

 707 total views,  1 views today

Siwoo Jung by Siwoo Jung
PUBLISHED: August 12, 2021 UPDATED: August 12, 2021
in Celltrion, Coronavirus, Medical, Medical industry
0
Celltrion pushes for broader use of its COVID-19 treatment 

Celltrion is trying to push for a more expansive use for Regkirona, its COVID-19 treatment, globally. The inhalable Regkirona has only been allowed to patients over 12 years of age and on patients with severe symptoms or those are in high-risk groups with mild symptoms.

On Wednesday, Celltrion said that it has asked the Ministry of Food and Drug Safety for permission to use it on COVID-19 patients over 12 years with mild and severe symptoms.

Approval for a clinical trial in Australia

Celltrion has further said that it has received approval from Australia’s Therapeutic Goods Administration (TGA) for phase one of the inhalable Regkirona. Twenty-four healthy people will be under trial in the first phase, and the next one will begin later this year.

Earlier, Celltrion had filed clinical data from its phase 3 study on the safety and efficacy of the drug on a broad range of age groups.

This version of Regkirona is going to be inhalable

Since July last year, Celltrion has been working with Inhalon Biopharma, a bio-company from the U.S., to develop this inhalable form of Regkirona.

Inhalon had started non-clinical studies on rodents in January. The company has decided to proceed with phase one of the trial after confirming the safety and tolerability of repeated doses of Regkirona.

Celltrion expects its experimental COVID-19 drug to further increase the reach and accessibility of antibody therapeutics.

Celltrion pushes for accessibility in more countries

Regkirona is currently under review by the European Medicines Agency, while Celltrion is in talks with the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization of its COVID-19 treatment.

Saudi Arabia, the UAE, Jordan, Iraq, and Morocco are some of the other countries where the company filed for Regkirona’s approval.

In July, Regkirona received an emergency use authorization from the Indonesian government to use the drug in the country.

What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: Celltrion HealthcarecoronavirusInhalonRegkirona

Related Posts

VUNO Signs Another Deal with Samsung Electronics
Medical

VUNO Signs Another Deal with Samsung Electronics

October 21, 2021
U.S.-based NeoImmuneTech (NIT) plans to raise around 96 billion won from IPO on the Korean Securities Dealers Automated Quotations (KOSDAQ) in March.
Medical

US-Based NeoImmuneTech Targets 96 Billion Won IPO in KOSDAQ

February 27, 2021
South Korea’s National Intelligence Service reveals North Korea attempted to hack Pfizer’s servers for sensitive COVID-19 vaccine technology.
Coronavirus

North Korea Attempts Pfizer Server Hack for COVID-19 Vaccine Tech

February 17, 2021
Samsung Biologics delivers first batch of Eli Lilly's COVID-19 antibody treatment.
Coronavirus

Samsung Biologics to Manufacture Eli Lilly‘s COVID-19 Antibody Treatment

November 19, 2020
VIRNECT launches AR 2.0 solutions for remote work in industrial sites.
AR

VIRNECT AR Solution 2.0 Launches for Remote Work in Industrial Sites

October 3, 2020
The Digital Economy Forum 2020 (DEF2020) special session featured five innovative startups providing solutions to the ongoing COVID-19 pandemic.
Coronavirus

DEF2020 Special Session: 5 Rising Startups Responding to the Pandemic

September 16, 2020
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Robots to help Police Patrol in South Korea

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • South Korea plans Urban Air Mobility Air Taxi services by 2025

    0 shares
    Share 0 Tweet 0
  • SK On to introduce South Korea’s first LFP Battery Prototype

    0 shares
    Share 0 Tweet 0
  • South Korea to commercialize Quantum Cryptography Communications

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • Netmarble subsidiary Metaverse Entertainment’s K-Pop virtual girl band MAVE has a smashing online debut

    0 shares
    Share 0 Tweet 0
  • KT Continues to Accelerate Its ‘Digico’ Transformation

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |